PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6617596

Anticonvulsant drugs, cognitive function, and behavior.

M R Trimble·P J Thompson
View original source ↗Export metadata ↓

Abstract

Healthy volunteers as well as patients with epilepsy were studied for 2 weeks in a double-blind crossover design to determine the effect of anticonvulsant drugs on cognitive function and behavior. The healthy volunteers experienced significant deficits in performance with the four drugs examined, phenytoin, carbamazepine, sodium valproate, and clobazam. The most widespread changes were seen with phenytoin; carbamazepine, sodium valproate, and clobazam did not interfere with tests of memory function. The results of the patients' studies showed that (1) when anticonvulsants are reduced, patients receiving polytherapy improve their cognitive function; (2) patients with high serum levels of anticonvulsant drugs demonstrated more cognitive impairment than those with low levels; (3) when carbamazepine is substituted for another anticonvulsant, cognitive function is improved; and (4) in patients receiving monotherapy, high serum levels are linked to greater cognitive impairment than lower levels and the profile of changes differs between the drugs.

Explore related subjects

AnticonvulsantsAttentionBehaviorCognitionHumansMemoryMovementPsychological TestsClinical TrialControlled Clinical TrialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M R Trimble, P J Thompson. 1983. Anticonvulsant drugs, cognitive function, and behavior.. https://doi.org/10.1111/j.1528-1157.1983.tb04644.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗